| 摘要 |
<p>The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors ofβ-catenin. The disclosure also relates to applications in the treatment of ophthalmic conditions, such as macular degeneration and glaucoma, and pharmaceutical compositions comprising such alpha helix mimeticβ-catenin inhibitors.</p> |
